IRX reports Phase IIa data for citoplurikin in SCCHN

In September, IRX Therapeutics Inc. (New York, N.Y.) reported data from a Phase IIa trial in 27 patients with squamous cell carcinoma of the head and neck (SCCHN) showing that subcutaneous citoplurikin (IRX-2) reduced tumor size and led to a 5-year overall survival (OS) rate of 65%. In patients with a “large” change in lymphocyte infiltrate into tumors after treatment, the probability of survival at 5 years was >80% (p<0.05).

The open-label, U.S. trial is evaluating twice-daily injections of citoplurikin for 10 days in combination with cyclophosphamide, indomethacin and zinc. The most common treatment-related adverse events reported were nausea, injection-site pain, headache and dizziness...